Agenus Inc. Stock
Agenus Inc. Stock
Agenus is a biotechnology company focused on developing immunotherapies to treat cancer and other diseases. The company's product pipeline includes checkpoint inhibitors, which work by blocking proteins that help cancer cells evade detection by the immune system, as well as other immunotherapies designed to stimulate the body's immune response to tumors. Agenus has collaborations with large pharmaceutical companies including Merck, Incyte, and Gilead, and is actively working on bringing its products to market through clinical trials and regulatory approval. The company is listed on the NASDAQ stock exchange under the ticker symbol AGEN.
Pros and Cons of Agenus Inc. in the next few years
Pros
Cons
Performance of Agenus Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agenus Inc. | - | - | - | - | - | - | - |
| Ardelyx Inc. | 28.120% | 34.723% | 18.969% | 89.624% | 39.758% | 44.250% | - |
| Evolus Inc | 10.280% | 12.381% | -5.600% | 60.544% | 30.387% | 60.544% | - |
| Salarius Pharmaceuticals Inc. | 11.650% | 7.981% | 17.949% | -67.606% | -17.117% | -98.248% | -99.993% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.A general overview of Agenus Inc.'s (AGEN) financials portrays a mixed situation. The company is actively involved in the Biotechnology & Medical Research industry, which has the potential for high growth and innovative breakthroughs. While Agenus seems to be progressing in terms of revenue, it is struggling with mounting liabilities, negative equity, and concerns about cash flow. This article will dive deeper into the pros and cons of Agenus' financial situation to paint a clearer picture of the company's current standing.
Rising Revenue: A noteworthy positive aspect is the year-over-year (YoY) growth of Agenus' total revenue. For instance, from 2020 to 2021, revenue increased from $88.17 million to $295.67 million, which can be a sign of business expansion and successful commercialization efforts.
Decreasing Net Loss: The net income trend for Agenus has shown some improvement. For instance, net income losses have reduced from -$180.91 million in 2020 to -$22.93 million in 2021, which might indicate a potential path toward profitability.
Comments
News
Up 40%: Is This Red-Hot Growth Stock Still a Buy?
Last Friday, Agenus (NASDAQ: AGEN), an immuno-oncology player, saw its shares soar by a staggering 40.8%. This remarkable rally occurred seemingly without a clear catalyst. The company is set to
Down 75%. Is Agenus Stock a Buy on the Dip?
The past nine months have been rough ones to be an Agenus (NASDAQ: AGEN) shareholder. The stock has collapsed by about 75% from the peak it set last June.
Investment bank analysts on Wall Street who
Agenus (AGEN) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Agenus (NASDAQ: AGEN)Q4 2023 Earnings CallMar 14, 2024, 8:30 a.m. ET
Operator
Source Fool.com